01 — What is it?
DSIP has been studied in small controlled human sleep experiments. Results were mixed: some early studies reported sleep changes, while others concluded clinical significance was limited.
Database / Research Profiles / DSIP
RESEARCH PROFILE
DSIP
Delta sleep-inducing peptide • nonapeptide
Sleep / neurobiologySmall early human studies
EVIDENCE SNAPSHOTSMALL EARLY HUMAN STUDIES
Evidence is old, small and inconsistent; no modern large-scale validation establishes DSIP as a sleep treatment.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Sleep / neurobiology. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: YESPersonal dosing protocol: NOT PROVIDED
Evidence is old, small and inconsistent; no modern large-scale validation establishes DSIP as a sleep treatment.
04 — Mechanism / biology
DSIP has been studied in small controlled human sleep experiments. Results were mixed: some early studies reported sleep changes, while others concluded clinical significance was limited.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.